Low-Dose Cyclophosphamide Synergizes with Dendritic Cell-Based Immunotherapy in Antitumor Activity
Figure 3
CTX influences lymphocyte subsets in peripheral blood and draining lymph nodes of tumor-bearing mice. (a) The percentage of CD19+ cells was significantly decreased () in CTX-treated tumor-bearing mice. CD3+ cells were significantly increased () in the peripheral blood of CTX-treated tumor-bearing mice compared to untreated tumor-bearing mice. (b) CD19+ cells were significantly decreased () while CD3+ cells were significantly increased (), while the percentage of CD4+CD25+Foxp3+ cells was significantly decreased () in the splenocytes of CTX-treated mice compared to untreated tumor-bearing mice.
